Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Condition(s) studied

Investigational drug(s) / intervention(s)

peripheral blood sampling: It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics: * in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage II b, III or IV, Ann Arbor Classification).

Study summary

Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics:

* in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification).
* newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).

Eligibility

Primary outcome measure(s)

• evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA) — through study completion, an average of 2 year
  Determine the biological age of patients
• DNA methylation (methylation rate) — through study completion, an average of 2 year
  Determine the biological age of patients

Trial sites (1)

More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy